Your browser doesn't support javascript.
loading
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
Munseri, Patricia J; Kroidl, Arne; Nilsson, Charlotta; Joachim, Agricola; Geldmacher, Christof; Mann, Philipp; Moshiro, Candida; Aboud, Said; Lyamuya, Eligius; Maboko, Leonard; Missanga, Marco; Kaluwa, Bahati; Mfinanga, Sayoki; Podola, Lilly; Bauer, Asli; Godoy-Ramirez, Karina; Marovich, Mary; Moss, Bernard; Hoelscher, Michael; Gotch, Frances; Stöhr, Wolfgang; Stout, Richard; McCormack, Sheena; Wahren, Britta; Mhalu, Fred; Robb, Merlin L; Biberfeld, Gunnel; Sandström, Eric; Bakari, Muhammad.
Afiliação
  • Munseri PJ; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania; Venhalsan, Karolinska Institutet, Sodersjukhuset, Stockholm, Sweden.
  • Kroidl A; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
  • Nilsson C; The Public Health Agency of Sweden, Solna, Sweden; Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
  • Joachim A; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
  • Geldmacher C; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
  • Mann P; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany.
  • Moshiro C; Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
  • Aboud S; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
  • Lyamuya E; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
  • Maboko L; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania.
  • Missanga M; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania.
  • Kaluwa B; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania.
  • Mfinanga S; National Institute for Medical Research-Muhimbili Medical Research Centre, Dar es Salaam, Tanzania.
  • Podola L; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany.
  • Bauer A; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany.
  • Godoy-Ramirez K; The Public Health Agency of Sweden, Solna, Sweden.
  • Marovich M; Walter Reed Army Institute of Research (WRAIR), Rockville, MD, United States of America and The Henry M. Jackson Foundation, Rockville, MD, United States of America.
  • Moss B; Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, United States of America.
  • Hoelscher M; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
  • Gotch F; Imperial College, London, United Kingdom.
  • Stöhr W; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Stout R; Bioject Medical Technologies, 7180 SW Sandburg St, Tigard, Oregon, United States of America.
  • McCormack S; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
  • Wahren B; Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden.
  • Mhalu F; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
  • Robb ML; Walter Reed Army Institute of Research (WRAIR), Rockville, MD, United States of America and The Henry M. Jackson Foundation, Rockville, MD, United States of America.
  • Biberfeld G; The Public Health Agency of Sweden, Solna, Sweden; Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden.
  • Sandström E; Venhalsan, Karolinska Institutet, Sodersjukhuset, Stockholm, Sweden.
  • Bakari M; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
PLoS One ; 10(4): e0119629, 2015.
Article em En | MEDLINE | ID: mdl-25875843
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / Infecções por HIV / Vacinas contra a AIDS / Vacinas de DNA Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male País como assunto: Africa Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Virais / Infecções por HIV / Vacinas contra a AIDS / Vacinas de DNA Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male País como assunto: Africa Idioma: En Ano de publicação: 2015 Tipo de documento: Article